Multimodal Mesothelioma Treatment Doubles Survival in Mexican Study
Researchers at Mexico’s National Cancer Institute say multimodal mesothelioma treatment with chemotherapy, surgery, and radiation can slow tumor growth and improve survival. Their new study of patients with advanced pleural mesothelioma produced a median survival of nearly two years. That is almost twice as long as average for pleural mesothelioma. The researchers say the key is a multimodal mesothelioma treatment approach that attacks tumors from three different angles. Chemotherapy Alone is Rarely Enough Chemotherapy is still the main treatment for most patients with pleural mesothelioma. The FDA approved pemetrexed (Alimta) in 2004. Until the recent approval of a combination of Opdivo and Yervoy, Alimta was the only drug for mesothelioma. It is still the main component in mesothelioma chemotherapy. But…